Drug Profile
AB 110
Alternative Names: AB-110Latest Information Update: 12 Jun 2022
Price :
$50
*
At a glance
- Originator Angiocrine Bioscience
- Class Gene therapies; Haematopoietic stem cells therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 31 Jan 2022 Angiocrine Bioscience completes a phase I trial in Haematological malignancies in USA (Parenteral) (NCT03483324)
- 28 May 2021 No recent reports of development identified for phase-I development in Haematological-malignancies in USA (Parenteral)
- 24 Apr 2018 Phase-I clinical trials in Haematological malignancies in USA (Parenteral) (NCT03483324)